PYPD
Polypid Ltd (PYPD)
Healthcare • NASDAQ • $4.38-1.24%
- Symbol
- PYPD
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $4.38
- Daily Change
- -1.24%
- Market Cap
- $83.58M
- Trailing P/E
- N/A
- Forward P/E
- -4.74
- 52W High
- $5.12
- 52W Low
- $2.44
- Analyst Target
- $12.25
- Dividend Yield
- N/A
- Beta
- 1.41
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Company websiteResearch PYPD on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.